Sichenzia Ross Friedman Ference LLP Represents Israeli Company Can-Fite BioPharma on $9.0M Public Offering of ADSs
New York, NY – Press Release – September 22, 2015 –Securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that the Firm has represented Israeli biotechnology company, Can-Fite BioPharma (NYSE: CANF)(TASE: CFBI) on a public offering with institutional investors where Can-Fite received $9 million in gross proceeds. Pursuant to the offering, Can-Fite will issue 2,068,966 registered American Depository Shares (ADSs) at a purchase price of $4.35 per ADS. For each ADS purchased, investors will receive an unregistered warrant to purchase one-half of an ADS at an exercise price of $5.25 per ADS. H.C. Wainwright & Co. acted as the sole placement agent for the offering.
The Sichenzia Ross Friedman Ference LLP team was led by Partner Gregory Sichenzia, Partner Ronen Kantor of the Israeli DTKGC-SRFF office and Gary Emmanuel and Avital Even-Shoshan in New York.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)